Tandem Diabetes Care reports first-quarter results on May 20 with the stock deep in a drawdown — down 39% over the past month and 17% in the past week alone to close at $12.82. The damage follows a punishing Q4-style print on May 7 that sent shares down 14% in a single session, with a further 21% erosion over the following five days. Tuesday's earnings call is therefore less a routine quarter and more a referendum on whether the investment case still holds.
Short sellers have added conviction into the collapse. SI climbed nearly 9% over the past week to reach 13.9% of the free float — a meaningful and elevated reading that makes the short side a genuine force here. The month-long picture is more nuanced: shorts peaked at over 17% of the float in early-to-mid April before retreating, suggesting some covering after the May 7 sell-off locked in gains. Borrow remains cheap at 0.48% APR, and with availability sitting near 940% — meaning roughly nine shares are available to borrow for every one already lent — there is no squeeze pressure in the lending market whatsoever. Options positioning is only mildly defensive: the put/call ratio of 0.91 is slightly above its 20-day average of 0.82, but barely half a standard deviation above the mean and well below the 52-week high of 1.17 touched as recently as May 7. For a stock in freefall, the options market is not screaming panic.
The debate on the Street is sharpening into a clear fault line. Bulls point to Tandem's pharmacy-channel transition and its new product pipeline as structural growth levers — Truist kept its Buy rating this week (May 11) even as it trimmed its target to $31, and Barclays held Overweight despite cutting to $55. The mean analyst target of roughly $30 implies more than 130% upside from current levels, though that gap likely reflects stale targets yet to fully reset after the May 7 collapse rather than a cohesive bullish case. B of A is the freshest signal: on May 18 — the day before the print — it cut its target from $35 to $25 while staying Neutral, a move that flags continued downward pressure on consensus. Bears worry that competition in automated insulin delivery, particularly from Omnipod 5, is structuring a ceiling on Tandem's US growth, and that the company's reliance on disposables and a US-heavy revenue mix limits how fast margins improve. Voya Financial made a notable entry as a top-ten holder last quarter, adding the full 4.3 million shares it now holds — a fresh institutional vote of confidence, but one placed before the stock's latest leg down.
The print will test whether management can frame the pharmacy-channel conversion as a revenue and margin story in progress rather than a business still searching for its footing after a rough first half.
See the live data behind this article on ORTEX.
Open TNDM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
